This market research report provides an overview of the current biologic sterile injectable market dynamics as well as what our survey respondents — all outsourcing decision makers — predict the market will look like in 2022. Key statistics include development-stage and marketed product volume, the proportion outsourced, and the number of CMOs required to complete the work. You can purchase the report or download a free preview by clicking here.
Despite the best efforts of those directly responsible for data integrity, human error will still find its way into the equation and undermine the efforts. Even the most mature organizations with the most evolved data integrity practices likely experience turnover or new hires who must be integrated into the organization’s cultures and operations.
By Panagiota (Pam) Rizos, associate director, external operations, global regulatory affairs and clinical safety, Merck & Co., Inc.
Here are the final five best practices that Merck undertook to effectively extend its capacity through strategic outsourcing, which focuses on building a strong foundation with external partners.
White Paper |
By Olindo Lazzaro and Max Brescia,AbbVie
Strict regulations regarding the manufacture of HPAPIs require that pharmaceutical companies and CMOs carefully select equipment, outline processes, and deploy appropriate containment strategies.
Article |
By Günter Jagschies,GE Healthcare Life Sciences
Antibodies continue to dominate. Analyzing the strategies employed by successful players in the field could provide invaluable lessons for those hoping to enter it.
Article |
By Stephen Lam and Jennifer Stone,Thermo Fisher Scientific
For small biopharma innovators steep development costs are compounded by the fact that large molecules are becoming increasingly complex and present serious clinical or manufacturing problems.
Article |
By Ken Langhorn,Charles Ross and Son Company
Finding the right mixing equipment isn’t as simple as selecting an item from a menu. This article is a guide to factors to consider when choosing pharmaceutical mixing equipment and vendors for a facility.
Article |
By Maria Barajas,West Pharmaceutical Services, Inc.
Today’s drug delivery systems are complex technologies that require close teamwork between biopharmaceutical companies and their drug delivery technology partners to develop innovative platforms.
Over the years, the pharma industry has recognized the need to change and develop more efficient processes. Thus, a new field of chemistry called process research was born.
This study presents how strategic enhancements to the sparge and agitation systems of Thermo Scientific HyPerforma SUBs have revealed the potential for a three- to four-fold improvement in mixing and mass transfer performance compared to legacy SUB designs.
